Person:
Bhagwat, Mandar

Profile Picture

Email Address

AA Acceptance Date

Birth Date

Research Projects

Organizational Units

Job Title

Last Name

Bhagwat

First Name

Mandar

Name

Bhagwat, Mandar
Author's Publications: search.filters.isAuthorOfPublication.ce2955c3-0e9f-47a6-a7ba-215fb0da1e46

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Publication
    Angular dose dependency of MatriXX TM and its calibration
    (John Wiley and Sons Inc., 2010) Wolfsberger, Luciant D.; Wagar, Matthew; Nitsch, Paige; Bhagwat, Mandar; Zygmanski, Piotr
    One of the applications of MatriXX (IBA Dosimetry) is experimental verification of dose for IMRT, VMAT, and tomotherapy. For cumulative plan verification, dose is delivered for all the treatment gantry angles to a stationary detector. Experimental calibration of MatriXX detector recommended by the manufacturer involves only AP calibration fields and does not address angular dependency of MatriXX. Angular dependency may introduce dose bias in cumulative plan verification if not corrected. For this reason, we characterized angular dependency of MatriXX and developed a method for its calibration. We found relatively large discrepancies in responses to posterior vs. anterior fields for four MatriXX (Evolution series) detectors (up to 11%), and relatively large variability of responses as a function of gantry angle in the gantry angle ranges of 91°–110° and 269°–260°. With our calibration method, the bias due to angular dependency is effectively removed in experimental verification of IMRT and VMAT plans. PACS number: 87.56Fc
  • Thumbnail Image
    Publication
    Clinical implementation of a novel applicator in high-dose-rate brachytherapy treatment of esophageal cancer
    (Termedia Publishing House, 2016) Buzurovic, Ivan; Hansen, Jorgen Lindberg; Bhagwat, Mandar; O'Farrell, Desmond; Friesen, Scott; Harris, Thomas C.; Damato, Antonio L.; Cormack, Robert; Martin, Neil; Devlin, Phillip
    Purpose In this study, we present the clinical implementation of a novel transoral balloon centering esophageal applicator (BCEA) and the initial clinical experience in high-dose-rate (HDR) brachytherapy treatment of esophageal cancer, using this applicator. Material and methods Acceptance testing and commissioning of the BCEA were performed prior to clinical use. Full performance testing was conducted including measurements of the dimensions and the catheter diameter, evaluation of the inflatable balloon consistency, visibility of the radio-opaque markers, congruence of the markers, absolute and relative accuracy of the HDR source in the applicator using the radiochromic film and source position simulator, visibility and digitization of the applicator on the computed tomography (CT) images under the clinical conditions, and reproducibility of the offset. Clinical placement of the applicator, treatment planning, treatment delivery, and patient's response to the treatment were elaborated as well. Results: The experiments showed sub-millimeter accuracy in the source positioning with distal position at 1270 mm. The digitization (catheter reconstruction) was uncomplicated due to the good visibility of markers. The treatment planning resulted in a favorable dose distribution. This finding was pronounced for the treatment of the curvy anatomy of the lesion due to the improved repeatability and consistency of the delivered fractional dose to the patient, since the radioactive source was placed centrally within the lumen with respect to the clinical target due to the five inflatable balloons. Conclusions: The consistency of the BCEA positioning resulted in the possibility to deliver optimized non-uniform dose along the catheter, which resulted in an increase of the dose to the cancerous tissue and lower doses to healthy tissue. A larger number of patients and long-term follow-up will be required to investigate if the delivered optimized treatment can lead to improved clinical outcomes.